<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168098">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01813799</url>
  </required_header>
  <id_info>
    <org_study_id>DA-9801</org_study_id>
    <nct_id>NCT01813799</nct_id>
  </id_info>
  <brief_title>Study of DA-9801 to Treat Diabetic Neuropathic Pain</brief_title>
  <official_title>Phase 2 Clinical Study to Evaluate DA-9801 Tablet's Effectiveness and Safety and to Decide Optimal Volume for Neuropathic Pains With Diabetic Neuropathy Patients as the Target</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in
      the treatment of pain associated with diabetic neuropathy. Subjects will receive either
      300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain
      score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and
      Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Average pain score reduction compared to baseline</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average pain score</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most severe pain score</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight pain score</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression of improvement</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average weekly rescue medication use</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>DA-9801 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9801 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9801 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-9801</intervention_name>
    <arm_group_label>DA-9801 300mg</arm_group_label>
    <arm_group_label>DA-9801 600mg</arm_group_label>
    <arm_group_label>DA-9801 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the age of 20 ~ 70

          -  Type I or Type II Diabetes

          -  HbA1c â‰¤11%

          -  Patients with diabetic neuropathic pain for at least 3 months

          -  Patients corresponding to average pain level of 4 points or more for 24 hours
             evaluated with 11-point Likert scale

        Exclusion Criteria:

          -  neuropathic pain due to other causes or another stronger pain other than neuropathic
             pain

          -  abnormal in blood pressure, weight, ALT/AST, Serum creatinine

          -  positive reaction in HIV, HBV, or HCV

          -  experience of suicide try or Mental Illness Medical History

          -  BDI(Beck Depression Inventory) grade exceeding 21 points chronic alcohol abuse
             history
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bongyeon Cha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeok Sang Gwon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Yeouido St. Mary's Hopspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inkyung Jeong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangdong Kyunghee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji Hyeon Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Guk Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungbook National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In Ju Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Min Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun Hee Jung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Wonju Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jyeong Hyeon Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mun Seok Nam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Hyeok Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Kyong Moon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong Hwa Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sejong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwan Pyo Ko, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeju National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae Seon Park, M.D., Ph.D.</last_name>
    <phone>82-2-63-250-2154</phone>
    <email>irb@cuh.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeon-ju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Seon Park, M.D., Ph.D.</last_name>
      <phone>82-63-250-1794</phone>
      <email>pts@chonbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Tae Seon Park, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>March 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
